Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study

2013 ◽  
Vol 21 (8) ◽  
pp. 560-567 ◽  
Author(s):  
C. Treloar ◽  
J. Rance ◽  
G. J. Dore ◽  
J. Grebely ◽  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Barriers And Facilitators ◽  
Treatment Setting ◽  
Substitution Treatment ◽  
Hepatitis C Virus Infection ◽  
Opioid Substitution Treatment ◽  
Assessment And Treatment ◽  
Opioid Substitution

scholarly journals Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study

2013 ◽  
Vol 57 (suppl_2) ◽  
pp. S62-S69 ◽  
Author(s):  
Maryam Alavi ◽  
Jason Grebely ◽  
Michelle Micallef ◽  
Adrian J. Dunlop ◽  
Annie C. Balcomb ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
People Who Inject Drugs ◽  
Hepatitis C Virus Infection ◽  
Assessment And Treatment ◽  
Opioid Substitution

Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study

2019 ◽  
Vol 70 (10) ◽  
pp. 2199-2205 ◽  
Author(s):  
Bernd Schulte ◽  
Christiane Sybille Schmidt ◽  
Lisa Strada ◽  
Moritz Rosenkranz ◽  
Ingo Schäfer ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
High Risk ◽  
Incidence Rates ◽  
Hcv Rna ◽  
High Risk Population ◽  
Substitution Treatment ◽  
Opioid Substitution Treatment ◽  
Hcv Antibody ◽  
Opioid Substitution

Abstract Background Hepatitis C virus (HCV) infection is highly prevalent among people who inject drugs (PWID). Accurate data on HCV prevalence and incidence rates among patients receiving opioid substitution treatment (OST) are needed to estimate the current and future burden of HCV infections in this high-risk population. Methods Baseline data from routine care were collected between October 2014 and June 2016 from randomly selected OST facilities in Germany. The primary outcome measure was the HCV status (antibody and RNA prevalence). Patients who were HCV antibody–negative at baseline were followed up after 12 months to calculate the HCV incidence rate. Results Sixty-three facilities from 14 German Federal States provided clinical data for a total of 2466 OST patients. HCV antibody and HCV RNA prevalence were 58.8% (95% confidence interval [CI], 56.8%–60.8%) and 27.3% (95% CI, 25.5%–29.2%), respectively. At baseline, a total of 528 patients (21.4%) had previously undergone antiviral treatment. Moreover, lower HCV RNA prevalence was associated with female gender, employment, younger age, and shorter duration of OST and opioid dependence. The HCV incidence rate was 2.5 cases per 100 person-years. Conclusions The low HCV RNA prevalence and HCV incidence rates confirm that OST in Germany is an effective setting both for treating chronic HCV infections and for preventing new infections among PWID. Scaling up the provision of OST, HCV testing, and HCV treatment among OST patients are important public health strategies for reducing HCV infections in this high-risk population.

Sign in / Sign up

Export Citation Format

Share Document